Houston Metro Urology | Research Department

Research site
4223 Richmond Avenue Suite 200, Houston, Texas, United States of America

Site insights

Top conditions

Top treatments

Abiraterone Acetate
Prednisone Versus Abiraterone Acetate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 29 total trials

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Met...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: Abiraterone with Prednisone or Enzalutamide
Drug: 177Lu-PSMA-I&T

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensi...

Metastatic Castrate-sensitive Prostate Cancer
Drug: Androgen-deprivation Therapy (ADT)
Drug: Apalutamide

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib comb...

Active, not recruiting
Prostatic Neoplasms, Castration-Resistant
Drug: Cetrelimab 480 mg
Drug: Niraparib 200 mg

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting
Metastatic Castration-sensitive Prostate Cancer
Drug: Placebo for Niraparib
Drug: Niraparib

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting
Castration-Resistant Prostatic Cancer
Drug: Abiraterone Acetate
Drug: Placebo

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder canc...

Active, not recruiting
Non-muscle Invasive Bladder Cancer
Drug: Bacillus Calmette-Guerin
Drug: PF-06801591

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Bladder Cancer
Biological: Cetrelimab
Biological: BCG Vesiculture

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Urinary Bladder Neoplasms
Drug: TAR-200
Radiation: Conventional radiation therapy

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Non-Muscle Invasive Bladder Neoplasms
Drug: Mitomycin C
Drug: Gemcitabine

Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects wi...

Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
Device: INTIBIA Non-Therapeutic
Device: INTIBIA Therapeutic

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting
Hormone Sensitive Prostate Cancer
Prostate Cancer
Drug: Enzalutamide
Drug: Placebo (No longer applicable in Open Label study period)

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

Trial sponsors

Pfizer logo
Boston Scientific logo
Veru logo
Allergan logo
Coloplast logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems